Can You Get Mounjaro on the NHS for Weight Loss?

What NICE actually decided, and why most people still can't get it on the NHS

NICE published its appraisal of tirzepatide in December 2024, recommending Mounjaro as a cost-effective NHS treatment for weight management in adults. The evidence base underpinning that decision was substantial: the SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average body-weight reductions of around 20–21% at the highest dose over 72 weeks in thousands of adults with obesity. That kind of result is what persuaded NICE.

But a positive NICE appraisal does not flip a switch. NHS England is implementing tirzepatide in a phased rollout precisely because demand is expected to be enormous. The phases are tied to clinical complexity, sicker patients with more conditions come first. If you have read that Mounjaro is now available on the NHS and assumed that applies to you, it is worth checking the specifics carefully. The NICE technology appraisal (TA1026) sets the framework; NHS England decides the operational sequence.

One thing that catches people out: even once your cohort opens, you still need to be referred into an appropriate service and meet your local criteria. Access is not automatic.

The NHS rollout phases, who qualifies and when

The rollout follows a stepped timeline. From June 2025, NHS tirzepatide became available for adults with a BMI of 40 or above who have four or more of the five qualifying conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. That is a narrow group.

From around June 2026 (Cohort 2, activated on 23 June 2026) the threshold shifts to BMI 35–39.9, still requiring four or more of those conditions. From around March 2027, the condition count drops to three, at BMI 40 or above. Subsequent cohorts will gradually bring in lower BMI ranges and fewer comorbidities, but the full rollout runs to 2029 or beyond under current planning.

For context on how NHS access sits alongside private routes, the NHS Mounjaro weight loss page goes deeper on commissioning detail. If you are also weighing up whether the treatment itself is right for you, the safety profile overview is a useful companion read.

One practical note: if you are thinking about this around a bank holiday or the start of a new month, NHS waiting lists do not speed up, but private services like ours can still take and review consultations on working days year-round.

What to do if you don't yet qualify on the NHS

If you fall outside the current NHS cohort (perhaps your BMI is 33, or you have two conditions rather than four) you have two realistic options. You wait, which may mean years. Or you access treatment privately through a pharmacy that operates legally within the UK supply chain.

Private prescribing follows the licensed eligibility from Mounjaro's SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, pre-diabetes, high cholesterol, or obstructive sleep apnoea. That threshold is considerably lower than the current NHS cohort requirements. A prescriber still assesses every case, eligibility numbers are a starting point, not a guarantee of approval.

The options for getting Mounjaro in the UK are worth reading if you want a clear comparison of what each route involves. For a step-by-step picture of the private route specifically, how to get Mounjaro for weight loss covers the process from consultation to delivery. There is also a broader look at weight-loss treatment options if you are still deciding which medicine suits your situation.

The private route: what it does and doesn't change

Going private does not bypass the prescription requirement, that holds regardless of route. What it does bypass is the waiting list and the cohort restriction. At a GPhC-registered pharmacy, a GPhC-registered Independent Prescriber reviews your consultation on the same day. There is no NHS referral needed and no queue for a specialist service.

Cost is the obvious trade-off. Eli Lilly raised Mounjaro's UK list price significantly from September 2025; private prices since then typically range from around £149 to £375 per month depending on dose and provider, as reported widely at the time of the change. For a full picture of what those prices include (or don't) the Mounjaro cost breakdown is a useful reference before you compare providers. The short version: a legitimate private price covers a prescription and clinical assessment; a suspiciously low number almost certainly does not.

If you want to understand the full picture of what Mounjaro is and how it works before deciding anything, the Mounjaro overview is the place to start. And for those ready to take a next step, checking your eligibility with our prescribers costs nothing and takes a few minutes.